Prostate cancer ranks among the most prevalent malignant tumors in males. Early intervention and diligent surveillance are essential for enhancing patient prognosis. In recent years, urinary exosomes have garnered significant attention as crucial mediators of intercellular communication. Non-coding RNAs (ncRNAs) found in urinary exosomes are thought to play crucial roles in tumorigenesis and development. Therefore, investigating their potential applications in prostate cancer is of significant importance. Compared to imaging examinations, biomarkers have the advantages of being less traumatic and more repeatable. Furthermore, certain urinary exosomes ncRNAs are significantly up-regulated in prostate cancer patients and have good diagnostic and prognostic value. This suggests that urinary exosomes ncRNAs can serve as potential biomarkers, providing new insights for early detection and personalized treatment of prostate cancer.

Yesong Zou, Zhongxiang Zhao, Qian Lv, Xiaofu Qiu. Application of Urinary Exosomal Non-coding RNA as Biomarker in Prostate Caner. Academic Journal of Medicine & Health Sciences (2024), Vol. 5, Issue 12: 21-27. https://doi.org/10.25236/AJMHS.2024.051204.

[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. Journal of the National Cancer Center, 2024,4(1):47-53.

[2] Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study[J]. N Engl J Med, 2009, 360(13): 1320-1328

[3] CHEN R, SJOBERG DD , HUANG Y, et al. Prostate specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies compared with western cohorts. J Urol, 2017, 197 (1) : 90-96.

[4] Zeuschner P, Linxweiler J, Junker K. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev Mol Diagn. 2020 Feb;20(2):151-167. doi: 10.1080/14737159.2019.1665998. Epub 2019 Sep 18. PMID: 31499007.

[5] Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002 Aug;2(8):569-79. doi: 10.1038/nri855. PMID: 12154376.

[6] Trams EG, Lauter CJ, Salem N Jr, Heine U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta. 1981;645:63–70

[7] Arienti G, Carlini E, Verdacchi R, Cosmi EV, Palmerini CA. Prostasome to sperm transfer of CD13/aminopeptidase N (EC 3.4.11.2). Biochim Biophys Acta. 1997;1336:533–8.

[8] Stegmayr B, Brody I, Ronquist G. A biochemical and ultrastructural study on the endogenous protein kinase activity of secretory granule membranes of prostatic origin in human seminal plasma. J Ultrastruct Res. 1982;78:206–14.

[9] Pan BT, Johnstone RM. Fate of the transferrin receptor during matura-tion of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983;33:967–78.

[10] Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183:1161–72.

[11] Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4:594–600.

[12] Cui X, Fu Q, Wang X, Xia P, Cui X, Bai X, Lu Z. Molecular mechanisms and clinical applications of exosomes in prostate cancer. Biomark Res. 2022 Jul 29;10(1):56. doi: 10.1186/s40364-022-00398-w. PMID: 35906674; PMCID: PMC9338661.

[13] Zhou H, Yuen P S, Pisitkun T, et al. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery.Kidney Int, 2006, 69(8): 1471-1476

[14] Xie Zhe, Li Yifan, Wang Xiaoxiang, et al. Advances in the Research of Exosomal Circular RNA in Urological Tumors[J]. Progress in Biochemistry and Biophysics, 2022, 49(12): 2342-2354. DOI: 10.16476/j.pibb.2022.0048

[15] Li Bo, Jiang Yan, Lü Daojun, et al. Research progress on exosomal non-coding RNA in the diagnosis and treatment of prostate cancer[J]. Journal of the Academy of Military Medical Sciences, 2019, 40(04): 395-397.

[16] Zeuschner P, Linxweiler J, Junker K. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev Mol Diagn. 2020 Feb;20(2):151-167. doi: 10.1080/14737159.2019.1665998. Epub 2019 Sep 18. PMID: 31499007.

[17] Wang J, Samuels DC, Zhao S, Xiang Y, Zhao YY, Guo Y. Current Research on Non-Coding Ribonucleic Acid (RNA). Genes (Basel). 2017;8(12). Epub 2017/12/06. doi: 10.3390/genes8120366. PubMed PMID: 29206165; PubMed Central PMCID: PMCPMC5748684.

[18] Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic metastasis. Nature. 2015 Nov 19;527(7578):329-35. doi: 10.1038/nature15756. Epub 2015 Oct 28. PMID: 26524530; PMCID: PMC4788391.

[19] Wan G, Lim Q and Too HP, High-performance quantification of mature microRNAs by real-time RT-PCR using deoxyuridine-incorporated oligonucleotides and hemi-nested primers[J]. Rna-A Publication of The Rna Society, 2010, 16: 1436-1445

[20] Gao Ya-Hao, Cui Chang-Meng. The Role of Exosomal miRNAs in Common Urological Tumors[J]. Journal of Jining Medical College, 2023, 46(04): 283-286.

[21] Du J, Yang S, An D, Hu F, Yuan W, Zhai C, Zhu T. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res. 2009 Apr;19(4):487-96. doi: 10.1038/cr.2009.34. PMID: 19308091.

[22] Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as Biomarkers for Prostate Cancer. Front Genet. 2013;4:36.

[23] Endzeliņš E, Melne V, Kalniņa Z, Lietuvietis V, Riekstiņa U, Llorente A, et al.Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review. Mol Cancer. 2016;15:41.

[24] Valentino A, Reclusa P, Sirera R, Giallombardo M, Camps C, Pauwels P, et al.Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. Clin Transl Oncol. 2017;19:651–7.

[25] Lee H, Kang SJ, Lee J, Park KH, Rhee WJ. Isolation and Characterization of Urinary Extracellular Vesicles from Healthy Donors and Patients with Castration-Resistant Prostate Cancer. Int J Mol Sci. 2022 Jun 27;23(13):7134. doi: 10.3390/ijms23137134. PMID: 35806139; PMCID: PMC9266865.

[26] Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, Sandvig K, Linē A, Llorente A. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017 Oct 5;16(1):156. doi: 10.1186/s12943-017-0726-4. PMID: 28982366; PMCID: PMC5629793.

[27] Shin S, Park YH, Jung SH, Jang SH, Kim MY, Lee JY, Chung YJ. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer. NPJ Genom Med. 2021 Jun 11;6(1):45. doi: 10.1038/s41525-021-00212-w. PMID: 34117264; PMCID: PMC8196022.

[28] Matsuzaki K, Fujita K, Tomiyama E, Hatano K, Hayashi Y, Wang C, Ishizuya Y, Yamamoto Y, Hayashi T, Kato T, Jingushi K, Kawashima A, Ujike T, Nagahara A, Uemura M, Tsujikawa K, Nonomura N. MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancer. Transl Androl Urol. 2021 Apr;10(4):1918-1927. doi: 10.21037/tau-20-421. PMID: 33968679; PMCID: PMC8100845.

[29] Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012 Feb 14;106(4):768-74. doi: 10.1038/bjc.2011.595. Epub 2012 Jan 12. PMID: 22240788; PMCID: PMC3322952.

[30] Li Y, Ji J, Lyu J, Jin X, He X, Mo S, Xu H, He J, Cao Z, Chen X, Xu Y, Wang L, Wang F. A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study. Cancers (Basel). 2021 Aug 13;13(16):4075. doi: 10.3390/cancers13164075. PMID: 34439239; PMCID: PMC8393262.

[31] Işın M, Uysaler E, Özgür E, Köseoğlu H, Şanlı Ö, Yücel ÖB, Gezer U, Dalay N. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease. Front Genet. 2015 May 6;6:168. doi: 10.3389/fgene.2015.00168. PMID: 25999983; PMCID: PMC4422020.

[32] Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, Chen D, Gu J, He X, Huang S. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015 Aug;25(8):981-4. doi: 10.1038/cr.2015.82. Epub 2015 Jul 3. PMID: 26138677; PMCID: PMC4528056.

[33] Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022 Mar;19(3):188-206. doi: 10.1038/s41571-021-00585-y. Epub 2021 Dec 15. PMID: 34912049.

[34] Tao Wen, He Tao, He Yadi, et al. Preliminary study on the diagnostic value of urinary exosomal circ_0040507 combined with PSA for prostate cancer[J]. Xin Yi Xue, 2020, 51(6): 455-458.

[35] Lorenc T, Klimczyk K, Michalczewska I, Słomka M, Kubiak-Tomaszewska G, Olejarz W. Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy. Int J Mol Sci. 2020 Mar 19;21(6):2118. doi: 10.3390/ijms21062118. PMID: 32204455; PMCID: PMC7139716.

[36] Ahadi A. Functional roles of lncRNAs in the pathogenesis and progression of cancer. Genes Dis. 2020 Apr 21;8(4):424-437. doi: 10.1016/j.gendis.2020.04.009. PMID: 34179307; PMCID: PMC8209321.

[37] Yan S, Wang P, Wang J, Yang J, Lu H, Jin C, Cheng M, Xu D. Long Non-coding RNA HIX003209 Promotes Inflammation by Sponging miR-6089 via TLR4/NF-κB Signaling Pathway in Rheumatoid Arthritis. Front Immunol. 2019 Sep 18;10:2218. doi: 10.3389/fimmu.2019.02218. PMID: 31620132; PMCID: PMC6759987.

[38] Yang X, Wang L, Li R, Zhao Y, Gu Y, Liu S, Cheng T, Huang K, Yuan Y, Song D, Gao S. The long non-coding RNA PCSEAT exhibits an oncogenic property in prostate cancer and functions as a competing endogenous RNA that associates with EZH2. Biochem Biophys Res Commun. 2018 Jul 12;502(2):262-268. doi: 10.1016/j.bbrc.2018.05.157. Epub 2018 May 26. PMID: 29803673.

[39] Zhang H, Li M, Zhang J, Shen Y, Gui Q. Exosomal Circ-XIAP Promotes Docetaxel Resistance in Prostate Cancer by Regulating miR-1182/TPD52 Axis. Drug Des Devel Ther. 2021 May 3;15:1835-1849. doi: 10.2147/DDDT.S300376. PMID: 33976535; PMCID: PMC8106459.

[40] Greene J, Baird AM, Casey O, Brady L, Blackshields G, Lim M, O'Brien O, Gray SG, McDermott R, Finn SP. Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep. 2019 Jul 24;9(1):10739. doi: 10.1038/s41598-019-47189-2. PMID: 31341219; PMCID: PMC6656767.

[41] Zhong C, Wu K, Wang S, Long Z, Yang T, Zhong W, Tan X, Wang Z, Li C, Lu J, Mao X. Autophagy-related circRNA evaluation reveals hsa_circ_0001747 as a potential favorable prognostic factor for biochemical recurrence in patients with prostate cancer. Cell Death Dis. 2021 Jul 22;12(8):726. doi: 10.1038/s41419-021-04015-w. Erratum in: Cell Death Dis. 2021 Aug 4;12(8):768. doi: 10.1038/s41419-021-04051-6. PMID: 34294687; PMCID: PMC8298711.